These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11120284)

  • 1. Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.
    Wietzke P; Braun F; Ringe B; Ramadori G
    Transplant Proc; 2000 Nov; 32(7):2539-42. PubMed ID: 11120284
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
    Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
    Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
    [No Abstract]   [Full Text] [Related]  

  • 3. Summaries for patients. Sustained virologic response in hepatitis C.
    Ann Intern Med; 2007 Nov; 147(10):I47. PubMed ID: 18025441
    [No Abstract]   [Full Text] [Related]  

  • 4. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
    Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
    Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection.
    Beckebaum S; Cicinnati VR; Karliova M; Dirsch O; Erim Y; Frilling A; Malago M; Broelsch CE; Treichel U; Gerken G
    Transplant Proc; 2003 Sep; 35(6):2080-1. PubMed ID: 14529846
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.
    Mazzaferro V; Regalia E; Pulvirenti A; Tagger A; Andreola S; Pasquali M; Baratti D; Romano F; Palazzo U; Zuin M; Bonino F; Ribero ML; Gennari L
    Transplant Proc; 1997; 29(1-2):519-21. PubMed ID: 9123113
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
    Veldt BJ; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
    Ann Intern Med; 2007 Nov; 147(10):677-84. PubMed ID: 18025443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of interferon-alpha and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shaharabani E; Bar-Nathan N; Shapira Z; Tur-Kaspa R
    Transplant Proc; 2000 Jun; 32(4):714-6. PubMed ID: 10856556
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
    Narayanan Menon KV; Poterucha JJ; El-Amin OM; Burgart LJ; Kremers WK; Rosen CB; Wiesner RH; Charlton M
    Liver Transpl; 2002 Jul; 8(7):623-9. PubMed ID: 12089717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
    Götz G; Schön MR; Haefker A; Neuhaus R; Berg T; Hopf U; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2104-6. PubMed ID: 9723407
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
    Selzner N; Renner EL; Selzner M; Adeyi O; Kashfi A; Therapondos G; Girgrah N; Herath C; Levy GA; Lilly L
    Transplantation; 2009 Nov; 88(10):1214-21. PubMed ID: 19935376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
    Lengyel G; Kóbori L; Fehérvári I; Nemes B; Görög D; Patonai A; Sárváry E; Varga M; Perner F; Fehér J
    Orv Hetil; 2003 Nov; 144(48):2367-70. PubMed ID: 14753031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
    Testino G; Sumberaz A; Ravetti G; Gentile R; Ansaldi F; Icardi G
    Dig Liver Dis; 2006 Nov; 38(11):864-5. PubMed ID: 16945599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.